The Australian Study of HIV and Injecting Drug Use. Part I: Prevalence for HIV, hepatitis B and hepatitis C among injecting drug users in four Australian cities
Access Status
Authors
Date
1997Type
Metadata
Show full item recordCitation
Source Title
Faculty
Remarks
Originally published in Drug and Alcohol Review 1997 16(3) pp. 207-214
Copyright Taylor and Francis
A link at the Taylor and Francis web site available at http://www.tandf.co.uk
Collection
Abstract
The objective of this study was to assess differences in HIV, hepatitis B and hepatitis C seroprevalence among injecting drug users (IDU) in four Australian cities. Eight hundred and seventh-two current IDU were recruited in approximately equal numbers from each of Adelaide, Melbourne, Perth and Sydney, and interviewed individually using a structured questionnaire. Fingerprick blood samples were taken fiom the majority of respondents, and tested for past exposure to the three viruses. HIV and hepatitis B and C raw seroprevalences were compared across cities, and comparisons were made of age-standardized seroprevalences for hepatitis B and C. Three percent of all respondents were HIV seropositive; 1% (23% age-standardized) were hepatitis B seropositive and 55% (6096 age-standarized) were hepatitis C seropositive. There were general city differences and gender, sexual preference and treatment status group differences between the cities. Sydney respondents had the highest risk of infection for all three viruses in all comparisons. This was particularly striking for HIV among non-heterosexual men. Various explanations for the findings were considered, including city differences in demographic and drug use variables, underlying patterns of risk behaviour, and period/cohort effects. It was concluded that none of these explanations appeared to fit the pattern of findings, and that these probably represented true underlying differences in size of pools of infection. The reasons for this, however, cannot be ascertained from this study.
Related items
Showing items related by title, author, creator and subject.
-
Butler, K.; Day, C.; Dietze, P.; Bruno, R.; Alati, Rosa; Burns, L. (2015)© 2015 Elsevier Inc.. Background: Recent efforts in Australia to engage people who inject drugs (PWID) in hepatitis C (HCV) care have focussed on opioid substitution treatment (OST) services as a delivery site. This ...
-
Carruthers, Susan; Phillips, M.; Loxley, Wendy; Bevan, J. (1997)Researchers agree that while hepatitis B maybe in control, hepatitis C is present in epidemic proportions among injecting drug users and that current HIV prevention strategies have not been sufficient to halt the spread ...
-
Sacks-Davis, R.; Aitken, C.; Higgs, Peter; Spelman, T.; Pedrana, A.; Bowden, S.; Bharadwaj, M.; Nivarthi, U.; Suppiah, V.; George, J.; Grebely, J.; Drummer, H.; Hellard, M. (2013)Hepatitis C virus reinfection and spontaneous clearance of reinfection were examined in a highly characterisedcohort of 188 people who inject drugs over a five-year period. Nine confirmed reinfections and 17 possiblereinfections ...